Trial Profile

Phase 3 trial for ORIC-944 in mCRPC

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 27 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rinzimetostat (Primary)
Indications Prostate cancer
Focus Registrational; Therapeutic Use
Sponsors ORIC Pharmaceuticals

Most Recent Events

28 May 2025 According to ORIC Pharmaceuticals media release, The company announced a concurrent $125 million private placement financing that it expects will extend cash runway into the second half of 2027 and through the anticipated primary endpoint readout from the first ORIC-944 Phase 3 registrational trial in mCRPC.
04 Mar 2025 New trial record
25 Feb 2025 According to ORIC Pharmaceuticals media release, ORIC expects to initiate its first Phase 3 trial for ORIC-944 in mCRPC in 1H 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com